市場調查報告書
商品編碼
1541801
2024-2032 年適體市場報告(按類型(核酸、胜肽)、應用(診斷、治療、研究和開發等)和地區)Aptamers Market Report by Type (Nucleic Acid, Peptide), Application (Diagnostics, Therapeutics, Research and Developments, and Others), and Region 2024-2032 |
IMARC Group年全球適配體市場規模達26億美元。
適體是多功能寡核苷酸,可與特定標靶結合,包括蛋白質、胜肽、碳水化合物、小分子、毒素和活細胞。與抗體相比,它們具有可修飾性、非免疫原性、敏感性高、毒性低、易於製備、分子量低且不同製劑不存在差異等特點。因此,它們被廣泛用於治療和生物技術應用。除此之外,它們還被用作研究劑、診斷劑、生物感測器以及全球生物標記或藥物發現的工具。
癌症、神經退化性疾病、心血管疾病和後天免疫缺乏症候群(愛滋病)等危及生命的疾病的日益流行,是影響基於適體療法的新型有效檢測方法需求的關鍵因素之一。此外,增加核酸酶抗性並增強適體治療特性的化學修飾製程的出現正在推動市場成長。適配體市場的成長也可以歸因於為改善診斷設備和藥物及其載體而進行的研發(R&D)活動數量的增加。除此之外,由於適配體是化學合成的,消除了批次之間的差異並且需要更少的開發時間,因此它們的應用在全球範圍內廣泛增加。此外,私人組織正在與學術機構和研究實驗室合作,推出下一代產品並擴大其現有的市場佔有率。預計這將推動適體在廣泛的醫學治療以及食品和飲料 (F&B) 行業中的使用。
The global aptamers market size reached US$ 2.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.8 Billion by 2032, exhibiting a growth rate (CAGR) of 17.8% during 2024-2032.
Aptamers are versatile oligonucleotides that bind to a specific target, including proteins, peptides, carbohydrates, small molecules, toxins, and live cells. They are modifiable, nonimmunogenic, highly sensitive, less toxic, easy to prepare and have low molecular weight and no variation with different preparations as compared to antibodies. As a result, they are widely being used in therapeutic and biotechnological applications. Besides this, they are also utilized as research agents, diagnostics, biosensors, and tools for biomarker or drug discovery worldwide.
The growing prevalence of life-threatening diseases, such as cancer, neurodegenerative, cardiovascular, and acquired immunodeficiency syndrome (AIDS), represents one of the key factors influencing the demand for new and effective detection assays based on aptamer therapy. Moreover, the advent of the chemical modification process to increase the nuclease resistance and enhance the therapeutic properties of aptamers is bolstering the market growth. The aptamers market growth can also be accredited to the rising number of research and development (R&D) activities undertaken for improving diagnostic devices and drugs and their carriers. Apart from this, as aptamers are chemically synthesized, which eliminates batch-to-batch variation and requires less time for development, their application is extensively increasing across the globe. Furthermore, private organizations are collaborating with academic institutes and research laboratories to introduce next-generation products and expand their existing market presence. This is anticipated to fuel the usage of aptamers in a wide range of medical therapies, as well as in the food and beverage (F&B) industry.
IMARC Group provides an analysis of the key trends in each sub-segment of the global aptamers market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type and application.
Nucleic Acid
Peptide
Diagnostics
Therapeutics
Research and Developments
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aptagen LLC, Aptamer Group, Aptamer Sciences Inc., Aptus Biotech S.L., Base Pair Biotechnologies Inc., IBA GmbH, Kaneka Eurogentec S.A. (Kaneka Corporation), NeoVentures Biotechnology Inc., NOXXON Pharma, SomaLogic Inc., TriLink BioTechnologies LLC and Vivonics Inc.